ModerateAntiplatelet agents – P2Y12 receptor inhibitors×Selective immunosuppressants
Updated · Methodology
Mechanism
Leflunomide is converted during first pass through the gut wall and liver into active teriflunomide, which has a half-life of about 2 weeks (Arava SmPC, European Medicines Agency, EMA, section 5.2). Teriflunomide may be a weak CYP1A2 inducer in vivo, so drugs metabolised by CYP1A2 are used with caution during leflunomide treatment because their efficacy may be reduced (Arava SmPC, EMA, section 4.5). Clopidogrel is a prodrug: its active metabolite is formed mainly by CYP2C19 with contributions from CYP1A2, CYP2B6 and CYP3A4 (Plavix SmPC, EMA, section 5.2). The documents do not describe how CYP1A2 induction changes the effect of clopidogrel. The leflunomide SmPC also warns that hepatotoxic or haematotoxic drugs given with it may increase adverse effects. The clopidogrel SmPC describes haematological reactions with clopidogrel (EMA, sections 4.4 and 4.5).
Symptoms
The documents describe no symptoms specific to the combination. Leflunomide rarely causes severe liver injury, mostly in the first 6 months, and can cause haematological reactions, including pancytopenia (Arava SmPC, European Medicines Agency, EMA, section 4.4). Clopidogrel increases the risk of bleeding and haematological adverse reactions, and thrombocytopenia and neutropenia have been reported with thienopyridines (Plavix SmPC, EMA, section 4.4).
Management
The combination can be used with caution: the leflunomide SmPC calls for caution with drugs metabolised by CYP1A2, and clopidogrel is one of them (Arava and Plavix SmPCs, European Medicines Agency, EMA, sections 4.5 and 5.2). ALT and a complete blood count with differential and platelets are checked before leflunomide is started, every 2 weeks for the first 6 months and every 8 weeks thereafter. Monitoring is closer when haematotoxic drugs are given at the same time (Arava SmPC, EMA, sections 4.4 and 4.5). In serious haematological reactions, leflunomide and any concomitant myelosuppressive treatment are stopped and a leflunomide washout is started (Arava SmPC, EMA, section 4.4). If signs of bleeding appear on clopidogrel, a blood count and other tests are promptly considered (Plavix SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica Plavix 75 mg comprimidos recubiertos con película (clopidogrel) (2022)– AEMPS CIMA, ficha técnica Plavix 75 mg, nº registro 98069001 (EU/1/98/069), texto EMA, revisión diciembre 2022, secciones 4.2, 4.4 y 4.5
- EMA: Ficha técnica: Leflunomida, Arava (EU/1/99/118), secciones 4.4 y 4.5 (2026)– EMA, SmPC Arava 10 mg comprimidos recubiertos con película, EU/1/99/118, texto en CIMA nº registro 99118003, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4 y 4.5